Frontlight ResearchEarly access
CompletedPhase 3
A Study to Assess the Efficacy and Safety of Solriamfetol in Subjects With ADHD (FOCUS)
Key facts
- Who runs it
- Axsome Therapeutics, Inc.
- Where
- Austin, Bellaire, Berlin, Boston, Cherry Hill, Cincinnati, Clermont, Colorado Springs, Dallas, Doral, Draper, Encino, Everett, Gainesville, Garden Grove, Jacksonville, Kettering, Las Vegas, Lauderhill, Lincoln, Marietta, Media, Memphis, Miami Lakes, Mount Kisco, New York, Newport Beach, North Charleston, Oklahoma City, Orlando, Overland Park, Princeton, Raleigh, Riverside, Saint Charles, San Antonio, Santa Ana, Sherman Oaks, Torrance, and Walnut Creek, United StatesSee the 40 sites
- Trial code
- Status
- Completed
- Phase
- Phase 3
- People taking part
- 516 people enrolled
- Started
- 6 Jul 2023
- Ended
- 14 Mar 2025
- Type of study
- Interventional, 3 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Solriamfetol 150 mg
- Solriamfetol 300 mg
- Placebo
- Record updated
- 10 February 2026
Who can take part
- Age
- 18 years to 55 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 6 criteriaShow less
Who can take part
- Primary diagnosis of ADHD according to DSM-5 criteria
- Provides written informed consent to participate in the study before the conduct of any study procedures
- Male or female, aged 18 to 55 inclusive
Who cannot take part
- Prior exposure to solriamfetol/Sunosi, through either a clinical study or prescription
- Unable to comply with study procedures
- Medically inappropriate for study participation in the opinion of the investigator
Where in United States
- Austin, TexasHospital not named in the registry
- Bellaire, TexasHospital not named in the registry
- Berlin, New JerseyHospital not named in the registry
- Boston, MassachusettsHospital not named in the registry
- Cherry Hill, New JerseyHospital not named in the registry
- Cincinnati, OhioHospital not named in the registry
- Clermont, FloridaHospital not named in the registry
- Colorado Springs, ColoradoHospital not named in the registry
- Dallas, TexasHospital not named in the registry
- Doral, FloridaHospital not named in the registry
- Draper, UtahHospital not named in the registry
- Encino, CaliforniaHospital not named in the registry
- Everett, WashingtonHospital not named in the registry
- Gainesville, GeorgiaHospital not named in the registry
- Garden Grove, CaliforniaHospital not named in the registry
- Jacksonville, FloridaHospital not named in the registry
- Kettering, OhioHospital not named in the registry
- Las Vegas, NevadaHospital not named in the registry
- Lauderhill, FloridaHospital not named in the registry
- Lincoln, NebraskaHospital not named in the registry
- Marietta, GeorgiaHospital not named in the registry
- Media, PennsylvaniaHospital not named in the registry
- Memphis, TennesseeHospital not named in the registry
- Miami Lakes, FloridaHospital not named in the registry
- Mount Kisco, New YorkHospital not named in the registry
- New YorkHospital not named in the registry
- Newport Beach, CaliforniaHospital not named in the registry
- North Charleston, South CarolinaHospital not named in the registry
- Oklahoma City, OklahomaHospital not named in the registry
- Orlando, FloridaHospital not named in the registry
- Overland Park, KansasHospital not named in the registry
- Princeton, New JerseyHospital not named in the registry
- Raleigh, North CarolinaHospital not named in the registry
- Riverside, CaliforniaHospital not named in the registry
- Saint Charles, MissouriHospital not named in the registry
- San Antonio, TexasHospital not named in the registry
- Santa Ana, CaliforniaHospital not named in the registry
- Sherman Oaks, CaliforniaHospital not named in the registry
- Torrance, CaliforniaHospital not named in the registry
- Walnut Creek, CaliforniaHospital not named in the registry
About the trial
What the trial wants to find out
FOCUS (Forward Treatment of Attention Deficit and Hyperactivity Using Solriamfetol) is a Phase 3, multi-center, randomized, double-blind, placebo-controlled, parallel- group trial to assess the efficacy and safety of solriamfetol in adults with ADHD.
The 3 groups in the trial
- Solriamfetol 150 mgTreatment being tested
Up to 6 weeks
- Solriamfetol 300 mgTreatment being tested
Up to 6 weeks
- PlaceboPlacebo, for comparison
Up to 6 weeks
Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Phase 3, Randomized, Double-blind, Placebo-controlled Trial of Solriamfetol in Adults With ADHD.
- Publications
- Record updated
- 10 February 2026